S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Did You Miss the Gold Rush? Try These 2 Silver Stocks
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
TKO Group Knocks Out WrestleMania Event Record
Citi’s Results Say This About The Stock Market
Video Gaming Rebound: Electronic Arts or Take-Two, Who Wins?
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Did You Miss the Gold Rush? Try These 2 Silver Stocks
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
TKO Group Knocks Out WrestleMania Event Record
Citi’s Results Say This About The Stock Market
Video Gaming Rebound: Electronic Arts or Take-Two, Who Wins?
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Did You Miss the Gold Rush? Try These 2 Silver Stocks
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
TKO Group Knocks Out WrestleMania Event Record
Citi’s Results Say This About The Stock Market
Video Gaming Rebound: Electronic Arts or Take-Two, Who Wins?
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Did You Miss the Gold Rush? Try These 2 Silver Stocks
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
TKO Group Knocks Out WrestleMania Event Record
Citi’s Results Say This About The Stock Market
Video Gaming Rebound: Electronic Arts or Take-Two, Who Wins?

AC Immune (ACIU) Competitors

$2.74
+0.01 (+0.37%)
(As of 04/12/2024 08:50 PM ET)

ACIU vs. PRLD, PBYI, XBIT, NBTX, XERS, TSVT, GBIO, PROC, CRMD, and RAPT

Should you be buying AC Immune stock or one of its competitors? The main competitors of AC Immune include Prelude Therapeutics (PRLD), Puma Biotechnology (PBYI), XBiotech (XBIT), Nanobiotix (NBTX), Xeris Biopharma (XERS), 2seventy bio (TSVT), Generation Bio (GBIO), Procaps Group (PROC), CorMedix (CRMD), and RAPT Therapeutics (RAPT). These companies are all part of the "pharmaceutical preparations" industry.

AC Immune vs.

Prelude Therapeutics (NASDAQ:PRLD) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Prelude Therapeutics has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500. Comparatively, AC Immune has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.

79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 51.4% of AC Immune shares are owned by institutional investors. 79.5% of Prelude Therapeutics shares are owned by company insiders. Comparatively, 4.6% of AC Immune shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Prelude Therapeutics' return on equity of -37.51% beat AC Immune's return on equity.

Company Net Margins Return on Equity Return on Assets
Prelude TherapeuticsN/A -53.39% -48.01%
AC Immune N/A -37.51%-33.32%

Prelude Therapeutics presently has a consensus target price of $5.25, indicating a potential downside of 6.58%. AC Immune has a consensus target price of $16.00, indicating a potential upside of 483.94%. Given Prelude Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe AC Immune is more favorable than Prelude Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prelude Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
AC Immune
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

AC Immune has higher revenue and earnings than Prelude Therapeutics. AC Immune is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prelude TherapeuticsN/AN/A-$121.83M-$2.04-2.75
AC Immune$14.80M18.31-$60.41M-$0.71-3.86

AC Immune received 228 more outperform votes than Prelude Therapeutics when rated by MarketBeat users. Likewise, 62.32% of users gave AC Immune an outperform vote while only 48.08% of users gave Prelude Therapeutics an outperform vote.

CompanyUnderperformOutperform
Prelude TherapeuticsOutperform Votes
25
48.08%
Underperform Votes
27
51.92%
AC ImmuneOutperform Votes
253
62.32%
Underperform Votes
153
37.68%

In the previous week, Prelude Therapeutics had 2 more articles in the media than AC Immune. MarketBeat recorded 4 mentions for Prelude Therapeutics and 2 mentions for AC Immune. Prelude Therapeutics' average media sentiment score of 1.59 beat AC Immune's score of 0.83 indicating that AC Immune is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Prelude Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AC Immune
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Summary

AC Immune beats Prelude Therapeutics on 11 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACIU vs. The Competition

MetricAC ImmunePharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$270.98M$6.52B$5.06B$7.65B
Dividend YieldN/A3.03%2.95%3.94%
P/E Ratio-3.8616.89236.5919.38
Price / Sales16.44346.322,422.17102.91
Price / CashN/A31.9636.9430.98
Price / Book1.295.174.614.29
Net Income-$60.41M$136.04M$105.33M$214.57M
7 Day Performance-0.36%-2.28%-2.30%-2.30%
1 Month Performance-17.72%-0.84%-0.32%-0.06%
1 Year Performance22.32%5.68%14.56%8.81%

AC Immune Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRLD
Prelude Therapeutics
0.6317 of 5 stars
$4.99
+6.2%
$5.25
+5.2%
-30.8%$274.05MN/A-2.45128
PBYI
Puma Biotechnology
2.6781 of 5 stars
$5.83
+3.6%
$7.00
+20.1%
+74.5%$281.06M$235.60M12.67185Gap Down
XBIT
XBiotech
0 of 5 stars
$9.27
-4.7%
N/A+159.8%$282.27M$4.01M-11.3085Positive News
NBTX
Nanobiotix
1.7206 of 5 stars
$6.01
-4.8%
$11.00
+83.0%
N/A$283.25M$5.12M0.00101Upcoming Earnings
Gap Down
XERS
Xeris Biopharma
4.0817 of 5 stars
$2.02
flat
$4.88
+141.3%
-12.0%$283.71M$163.91M-4.49377Positive News
TSVT
2seventy bio
3.2744 of 5 stars
$5.63
+2.2%
$13.17
+133.9%
-45.9%$288.88M$100.39M-1.27274Short Interest ↑
GBIO
Generation Bio
2.6843 of 5 stars
$3.98
-8.5%
$8.00
+101.0%
-17.8%$264.59M$5.90M-2.03174
PROC
Procaps Group
3.0382 of 5 stars
$2.60
-1.9%
$4.50
+73.1%
-37.1%$293.33M$414.10M5.005,500
CRMD
CorMedix
1.4354 of 5 stars
$4.75
-0.2%
$13.00
+173.7%
+10.8%$260.36M$60,000.00-5.1682Short Interest ↑
News Coverage
Positive News
RAPT
RAPT Therapeutics
4.3868 of 5 stars
$8.44
+1.4%
$25.67
+204.1%
-45.2%$293.71M$1.53M-2.78131

Related Companies and Tools

This page (NASDAQ:ACIU) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners